SCHEMBL30457212

SCHEMBL30457212

COC(=O)C1CC(c2ccc(OC)c(C(=O)OC(C)(C)C)c2)=NO1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 4/20 0.71
HTT P42858 2/20 0.54
MAPT P10636 3/20 0.53
KDM4E B2RXH2 2/20 0.53
GAA P10253 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MAPK1 P28482 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 2/20 0.51
PDE4A P27815 3/20 0.50
PDE4B Q07343 3/20 0.50
PDE4C Q08493 3/20 0.50
PDE4D Q08499 3/20 0.50
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
PKM P14618 1/20 0.49
HPGD P15428 1/20 0.49
MAPK10 P53779 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25237352 1.00 MIF (0.71) MIFHTTMAPTKDM4EGAA
SCHEMBL25280295 0.86 MIF (0.78) MIFHTTMAPTKDM4EGAA
SCHEMBL26106388 0.86 MIF (0.63) MIFHTTMAPTKDM4EGAA
SCHEMBL30362053 0.86 MIF (0.63) MIFHTTMAPTKDM4EGAA
SCHEMBL7399375 0.84 MIF (1.00) MIFHTTMAPTKDM4EGAA
SCHEMBL26102340 0.80 MIF (0.58) MIFHTTMAPTKDM4EGAA
SCHEMBL30390740 0.80 MIF (0.58) MIFHTTMAPTKDM4EGAA
SCHEMBL18288854 0.76 PDE4A (0.84) MIFHTTMAPTKDM4EGAA
SCHEMBL25245392 0.76 MIF (0.41) MIFHTTMAPTKDM4EGAA
SCHEMBL30456597 0.76 MIF (0.41) MIFHTTMAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4448508-A1 BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-10-23 EP disclosed
WO-2023114823-A1 BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-22 WO disclosed